Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials

1 Duke University, Center for AIDS Research Central QA Unit, Durham, North Carolina, United States of America, 2 International AIDS Vaccine Initiative, Rockville, Maryland, United States of America, 3 Henry M. Jackson Foundation for the Advancement of Military Medicine–Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America, 4 Duke Human Vaccine Institute, Center for HIV/ AIDS Vaccine Immunology, Durham, North Carolina, United States of America, 5 HIV Vaccine Trials Network, Seattle, Washington, United States of America, 6 Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America, 7 International AIDS Vaccine Initiative, Johannesburg, Gauteng, South Africa, 8 Qualogy Ltd, Kettering, United Kingdom, 9 International AIDS Vaccine Initiative Core Laboratory, Imperial College London, London, United Kingdom, 10 AlphaVax Human Vaccines, Research Triangle Park, North Carolina, United States of America